<DOC>
	<DOCNO>NCT02297490</DOCNO>
	<brief_summary>The study explore allergy symptom experience grass pollen season compare symptom experience Environmental Exposure Chamber ( EEC ) . There 2 treatment study . Both treatment inject skin . Allergovit® Grasses work help body 's immune system get use grass-pollen grass pollen season begin may lead decreased sensitivity reduce allergy symptom grass season . Placebo treatment contain grass pollen mixture , expect reduce allergic symptom overtime .</brief_summary>
	<brief_title>Evaluation Utility EEC Assessing Efficacy SIT Pivotal Clinical Trials</brief_title>
	<detailed_description>This Phase II trial , one year observational/baseline phase follow one year double-blind placebo-controlled , randomized , treatment phase . Approx . 137 grass pollen-allergic subject 20 non-allergic subject enrol baseline phase study . The primary objective trial investigate relationship allergy symptom experience subject ( allergic non-allergic ) upon exposure grass pollen-allergen EEC allergy symptom experience subject grass pollen season .</detailed_description>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>IgEmediated seasonal allergic rhinitis/rhinoconjunctivitis without allergic asthma positive skin prick test specific IgE ≥ 0.70 kU/L mixture grass pollen allergens symptom score least 4 per day week follow peakpollen count baseline season undergone previous specific immunotherapy grass pollen allergens formulation le 5 year prior screen date currently undergo sort immunotherapy , ever undergone specific immunotherapy unknown allergen allergen expect interfere grass pollen season uncontrolled partly control asthma patient contraindication SIT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Environmental Exposure Chamber</keyword>
	<keyword>Specific Immunotherapy</keyword>
	<keyword>SIT</keyword>
	<keyword>SCIT</keyword>
</DOC>